Jixon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.15 M
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
- Revenue Growth 49.24%
- Profit Growth 28.83%
- Ebitda 28.85%
- Net Worth 51.64%
- Total Assets 181.51%
About Jixon Pharmaceuticals
Jixon Pharmaceuticals Private Limited (JPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 July 2016 (Eight years and six months 30 days old ). Its registered office is in Cuttack, Odisha, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M.
The company currently has active open charges totaling ₹1.00 M.
Rashmi Behera and Surendra Behera serve as directors at the Company.
Company Details
-
Location
Cuttack, Odisha, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33309OR2016PTC025471
-
Company No.
025471
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Jul 2016
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Jixon Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rashmi Behera
|
Director | 29-Sep-2017 | Current |
|
Surendra Behera
|
Director | 04-Jul-2016 | Current |
Financial Performance of Jixon Pharmaceuticals.
Jixon Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 49.24% increase. The company also saw a substantial improvement in profitability, with a 28.83% increase in profit. The company's net worth Soared by an impressive increase of 51.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jixon Pharmaceuticals?
In 2019, Jixon Pharmaceuticals had a promoter holding of 66.67% and a public holding of 33.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 May 2021 | Axis Bank Limited | ₹1.00 M | Open |
How Many Employees Work at Jixon Pharmaceuticals?
Jixon Pharmaceuticals has a workforce of 13 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jixon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jixon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
